| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 8 |
| Sex | Both Genders |
| Age Range | 18-29, 30-44 |
| Body Types | Overweight |
Two months supplementation of 120mg EGb-761 twice daily is able to reduce the oxidation of LDL and improve antioxidant status while also improving biomarkers of blood flow (cGMP) and reducing artherosclerotic buildup.
Both superoxide dismutase and glutathione peroxidase were increased as well as cAMP, and IL-6 as well as myeloperoxidase were reduced.
